230 related articles for article (PubMed ID: 35138909)
1. Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Lahman MC; Schmitt TM; Paulson KG; Vigneron N; Buenrostro D; Wagener FD; Voillet V; Martin L; Gottardo R; Bielas J; McElrath JM; Stirewalt DL; Pogosova-Agadjanyan EL; Yeung CC; Pierce RH; Egan DN; Bar M; Hendrie PC; Kinsella S; Vakil A; Butler J; Chaffee M; Linton J; McAfee MS; Hunter DS; Bleakley M; Rongvaux A; Van den Eynde BJ; Chapuis AG; Greenberg PD
Sci Transl Med; 2022 Feb; 14(631):eabg8070. PubMed ID: 35138909
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
[TBL] [Abstract][Full Text] [Related]
3. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
4. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
[TBL] [Abstract][Full Text] [Related]
5. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.
Uttenthal B; Martinez-Davila I; Ivey A; Craddock C; Chen F; Virchis A; Kottaridis P; Grimwade D; Khwaja A; Stauss H; Morris EC
Br J Haematol; 2014 Feb; 164(3):366-75. PubMed ID: 24422723
[TBL] [Abstract][Full Text] [Related]
6. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
7. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
8. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
[TBL] [Abstract][Full Text] [Related]
9. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA; Hagedoorn RS; Remst DFG; Assendelft DC; van der Steen DM; Wouters AK; van de Meent M; Kester MGD; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728869
[TBL] [Abstract][Full Text] [Related]
10. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
[TBL] [Abstract][Full Text] [Related]
12. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
Yao X; Matosevic S
Immunol Lett; 2024 May; 268():106881. PubMed ID: 38810886
[TBL] [Abstract][Full Text] [Related]
13. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
[TBL] [Abstract][Full Text] [Related]
15. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia.
Xie G; Ivica NA; Jia B; Li Y; Dong H; Liang Y; Brown D; Romee R; Chen J
Nat Biomed Eng; 2021 May; 5(5):399-413. PubMed ID: 33046866
[TBL] [Abstract][Full Text] [Related]
18. WT1 as a novel target antigen for cancer immunotherapy.
Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
[TBL] [Abstract][Full Text] [Related]
19. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.
Sergeeva A; Alatrash G; He H; Ruisaard K; Lu S; Wygant J; McIntyre BW; Ma Q; Li D; St John L; Clise-Dwyer K; Molldrem JJ
Blood; 2011 Apr; 117(16):4262-72. PubMed ID: 21296998
[TBL] [Abstract][Full Text] [Related]
20. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
